Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B for Taligen Therapeutics to bring in $65mm

Executive Summary

Taligen Therapeutics (candidates that regulate excess activation of the complement system) has raised $7.1mm out of a potential $65mm tranched Series B financing. First-time backers Alta Partners and Clarus Ventures, which each contribute a new board member, led and were joined by returning shareholders including Sanderling Ventures, Tango Ventures, and High Country Venture. The company will use the money to move its preclinical antibody fragment TA106 (asthma and AMD) and recombinant Factor H (choroidal neovascularization, inflammatory arthritis, ischemia-reperfusion injury, stroke, and spinal cord injury) into human testing.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies